News

Bionure and National Multiple Sclerosis Society Enter into a Collaboration to Support the Development of a	New Chemical Entity for Optic Neuritis and MS

09.01.2015

Bionure and National Multiple Sclerosis Society Enter into a Collaboration to Support the Development of a New Chemical Entity for Optic Neuritis and MS

PRESS RELEASE. JANUARY 9, 2015.

 

Bionure, Inc. a California-based late-preclinical drug development company, today announced that it has entered into a Sponsored Research Agreement with the National Multiple Sclerosis Society through Fast Forward, its commercial research subsidiary aimed at accelerating the development of new and improved therapies for MS. Under this agreement, Fast Forward will provide funding to Bionure for the late-preclinical development of BN201 to enable IND filling to support the Phase 1 clinical study in Acute Optic Neuritis (AON). Optic neuritis is often a first sign of multiple sclerosis.

 

Bionure’s BN201 is a New-Chemical Entity, first-in-class neuroprotective candidate in development for AON and has been recently granted with orphan designation status by the FDA. Beyond its neuroprotective activity in neurons, the compound has been shown to stimulate remyelination by differentiating OPCs into mature oligodendrocytes and promoting the formation of myelin sheaths around axons. Protecting the nervous system from damage and reversing that damage through myelin repair has the potential to restore function to people with optic neuritis and multiple sclerosis.


Press Release

back